Purpose: To evaluate the anatomical and functional results after ocriplasmin (JETREA, ThromboGenics NV, Iselin, NJ, USA) injection in patients with vitreomacular traction (VMT) with or without macular hole (MH). Methods: Fifteen prospective patients with VMT were treated with a single ocriplasmin injection and followed-up at baseline, 1 week, 1, 3 and 6 months. ETDRS best-corrected visual acuity (BCVA), intraocular pressure and...

Read More